High-Dose Vitamin D to Prevent Bone Loss in Men Aged 50 and Older Undergoing Androgen-Deprivation Therapy for Prostate Cancer

What this Trial Is About

Researchers are studying whether high-dose vitamin D can help prevent bone loss caused by androgen-deprivation therapy ADT in men with prostate cancer. This phase III trial focuses on men aged 50 and older who are undergoing ADT, which can weaken bones. Vitamin D helps the body absorb calcium, essential for strong bones, and the study aims to see if high doses of vitamin D can keep bones strong, reduce falls, and lessen fatigue in these patients. Participants are randomly assigned to one of two groups. One group receives high-dose vitamin D orally once a week for 52 weeks, while the other group receives a placebo on the same schedule. Both groups undergo blood collection and bone density scans during the study to monitor changes in bone health. Throughout the 52 weeks, participants will have bone density measured at multiple sites using dual-energy x-ray absorptiometry DXA, and researchers will track falls, fractures, quality of life, pain, fatigue, sleep, and daily activities through questionnaires and clinical records. The study includes regular assessments of blood vitamin D and calcium levels to ensure safety and effectiveness of the supplementation.

Vitamin D for Prostate Endocrine Therapy